Through significant financial commitments and pioneering regulations in AI medical technology, China is transforming healthcare delivery models while putting pressure on established global industry leaders.
A Race to Dominate AI Healthcare
China has established itself as a leading force in medical artificial intelligence over the previous five years through comprehensive initiatives that span AI-assisted radiology and pathology to predictive analytics for public health emergencies and hospital operations management. According to a Market Research Future report, China’s AI healthcare market reached a value of $12.5 billion in 2024 as public-private partnerships and state funding driven by supportive policy frameworks fueled its growth. One reason is the fast ageing population of China, which is creating pressure on the health system and leading to the need for scalable and efficient solutions. Another reason is the differences in access to health care between the urban and rural populations, which requires AI to standardize the quality of care. Aside from practical health care, the Chinese government considers medical AI as a priority to develop its technology, become more competitive, and secure its position as an innovation leader.
The Chinese government’s 2017 AI Development Plan marked the beginning of this growth by naming healthcare as one of its top sectors for AI development. Major players like Ping An Good Doctor, iFlytek, and Huawei Cloud have transitioned from basic AI tools like symptom checkers to comprehensive hospital management systems and telemedicine networks for remote areas.
AI systems have become integral components of healthcare operations across major urban areas. Major hospitals in Beijing, Shanghai, and Shenzhen implement AI systems which handle patient admissions, optimize staff scheduling, and forecast emergency room demand to assist clinicians with decision-making. AI tools now function as active elements in clinical workflows which determine the timing, location, and manner of patient care delivery.
Disruption Beyond Digital Diagnostics
While the global healthcare sector commonly associates artificial intelligence with digital triage systems and imaging diagnostic tools, China has expanded its AI healthcare applications well beyond those areas. AI applications now extend beyond disease detection to manage hospital logistics, monitor public health threats, and develop new treatment strategies from patient data analysis.
Tencent’s Miying platform stands as a significant example, having screened millions of patients to detect early signs of esophageal and lung cancers. The platform claims diagnostic accuracy rates that exceed those of some human radiologists, though independent researchers continue to rigorously confirm these results. Nonetheless, AI has integrated into Chinese clinical operations at an unmatched scale, developing swiftly with government support while bypassing much of the regulatory constraints that slow adoption in many Western healthcare systems. The speed of this development is made possible by China's sophisticated state and private actors, from state health institutions to Tencent, which provide data centers, a centralized health data collection system, and infrastructure to train and deploy AI models. Such unified public-private ecosystems and light-touch regulations are hard to reproduce in the absence of centralized institutional actors, fragmented data, and strong regulatory controls.
The application of AI technology to solve healthcare inequities throughout China's expansive rural areas is also expanding. Communities that suffer from inadequate specialist medical care now have access to AI diagnostic mobile units along with cloud services and telemedicine platforms supported by artificial intelligence. According to China Briefing, the delivery of healthcare has experienced a substantial transformation in regions of China that have long received inadequate services.
Regulatory Tailwinds and Risks
The Global News Wire has authorized more than 50 AI medical devices since 2020, exceeding the number of AI device approvals by the United States Food and Drug Administration during that timeframe. Chinese authorities have actively implemented a strategy to accelerate AI integration into healthcare systems as a dual strategy for improving national competitive standing and filling medical service shortages.
However, the accelerated deployment of these devices presents significant concerns regarding safety standards as well as regulatory effectiveness. A 2025 study by the Tsinghua University School of Medicine highlighted the risks of algorithmic bias, patient data privacy issues, and questioned the enduring reliability of AI decision-making under minimal regulatory supervision in medical contexts. The study warned that China's rapid AI healthcare adoption may result in ethical and safety standards being neglected — a double-edged sword balancing efficiency with the risk of harm. Take, for instance, AI-powered diagnostics at remote hospitals. Here, AI was used without the same oversight as in other cases. When AI diagnosis at a remote hospital missed early-stage lung lesions, leading to missed treatments, the situation garnered a lot of media attention but no regulatory response. This mirrors the original deployment of IBM’s Watson for Oncology in the U.S., which showed promise in helping cancer treatment but, based on poorly trained data, ended up suggesting dangerous treatment options. However, in the Chinese context, the scale of the failures is more amplified. In the U.S., there was an inherent regulatory framework that could course-correct for these sorts of failures. There was a strong chain of accountability and control. In China, these failures will have a much more devastating impact.
Global Implications and Competitive Pressure
In an effort to prevent a potential stagnation in AI healthcare technologies, western countries are racing to build the infrastructure to prevent China from outpacing them. They fear that if China’s AI medical systems in the realms of imaging and predictive analytics gain regulatory approval in other markets or if they spread in low- and middle-income countries due to low costs, they will steal the market from western giants like Philips, Siemens Healthineers, and GE Healthcare.
Some Chinese AI healthcare systems have been tested in hospitals in Southeast Asia, Africa, and the Middle East. Their advantages are cost-effective, fast deployment, and their fit in resource-constrained settings, making them an attractive option for countries wanting to leapfrog into modern healthcare systems without the cost of western technologies. Another reason these states have found AI solutions attractive is because many of them are affordable, relatively similar to China, with a similar set of structural issues (a fractured health care system, shortages of trained health care professionals, a rapidly growing population), and many countries see China’s offer of the technology as part of a “deal” including infrastructure, training, and data-sharing agreements as part of the Belt and Road Initiative. It also helps that Chinese tech companies may operate with fewer legal and intellectual property constraints, which makes it easier to customize and integrate the technology into the local health care system quickly.
Is It Sustainable?
While China’s model of AI healthcare is starting to achieve some successes, it faces severe sustainability challenges. Its uncoordinated data systems, local health infrastructure gaps, and misaligned international regulations could limit the mass-scale export of AI medical technologies.
For the long-term to be able to trust in AI-driven healthcare, long-term issues of ethics, algorithm transparency, and patient outcomes will need to be addressed with longitudinal studies and third-party assessments. Some critics argue that the perceived AI dominance of Chinese healthcare systems is largely a result of marketing aims and not scientifically validated medical performance. Without better outcomes, the sector is at risk of rushing into a mass-scale, general distrust of the healthcare system.
Conclusion: A Disruption in Progress
The progress of AI healthcare in China is not a short-term fad, but it cannot be considered a guaranteed transformative disruption. This state-led program is set to be a disruption in healthcare delivery in dense or infrastructure-poor areas. China’s rise to global leader or a cautionary tale in AI healthcare will be dependent on balancing speed and safety, innovation and fairness, and accountability in its ambitious mission.